BERGEN, Norway, Oct. 23, 2020 /PRNewswire/ -- BerGenBio ASA
(OSE:BGBIO), a clinical-stage biopharmaceutical company developing
novel, selective AXL kinase inhibitors for severe unmet medical
needs, is pleased to announce that it will host a virtual R&D
Day on 06 November 2020 from 13.00
CET.
The event will feature independent experts highlighting the
role of AXL kinase as an essential mediator of the biological
mechanisms underlying life-threatening diseases. The presentations
will focus on the role of AXL in specific disease areas including
oncology, fibrosis and infectious disease such as COVID-19. Each
presentation will be followed by a Q&A session.
A preliminary program for the event is outlined below. To
register, please click here.
Preliminary
Agenda
(times in CET)
|
13:00
|
Introduction - Richard Godfrey, Chief
Executive Officer, BerGenBio
|
|
13:10
|
AXL in
AML/MDS - Professor Sonja Loges, Director,
Department of Personalised Oncology, University Hospital
Mannheim and Division of Personalised Medical Oncology,
German Research Center - DKFZ (Heidelberg, Germany)
|
13:40
|
AXL in lung
cancer - Dr Matthew Krebs, Clinical Senior Lecturer in
Experimental Cancer Medicine and Honorary Consultant in Medical
Oncology, The Christie NHS Foundation Trust (Manchester,
UK)
|
14:10
|
AXL and
viruses/COVID-19 - Professor Wendy Maury, Professor of
Microbiology and Immunology, University of Iowa (Iowa City,
USA)
|
14:40
|
AXL in
fibrosis/IPF - Professor Cory
Hogaboam, Professor of Medicine, Cedars-Sinai Medical Center (Los
Angeles, USA)
|
15:10
|
Bemcentinib
clinical development plan - Hani Gabra, Chief Medical
Officer, BerGenBio
|
15:25
|
Concluding
remarks - Richard Godfrey, Chief Executive Officer,
BerGenBio
|
For further
information, please contact Consilium Strategic Communications at
bergenbio@consilium-comms.com or ir@bergenbio.com
|
About AXL
AXL kinase is a cell membrane receptor and an essential mediator
of the biological mechanisms underlying life-threatening diseases.
In cancer, AXL suppresses the body's immune response to tumours and
drives cancer treatment failure across many indications. AXL
expression defines a very poor prognosis subgroup in most cancers.
AXL inhibitors, therefore, have potential high value at the centre
of cancer combination therapy, addressing significant unmet medical
needs and multiple high-value market opportunities. Research has
also shown that AXL mediates other aggressive diseases.
About Bemcentinib
Bemcentinib (formerly known as BGB324), is a potentially
first-in-class selective AXL inhibitor in a broad phase II clinical
development programme. Ongoing clinical trials are investigating
bemcentinib in multiple solid and haematological tumours, in
combination with current and emerging therapies (including
immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular
catalytic kinase domain of AXL receptor tyrosine kinase and
inhibits its activity. Increase in AXL function has been linked to
key mechanisms of drug resistance and immune escape by tumour
cells, leading to aggressive metastatic cancers.
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused
on developing transformative drugs targeting AXL as a potential
cornerstone of therapy for aggressive diseases, including
immune-evasive, therapy resistant cancers. The company's
proprietary lead candidate, bemcentinib, is a potentially
first-in-class selective AXL inhibitor in a broad phase II clinical
development programme focused on combination and single agent
therapy in lung cancer, leukaemia and COVID-19. A first-in-class
functional blocking anti-AXL antibody, tilvestamab, is undergoing
phase I clinical testing. In parallel, BerGenBio is developing a
companion diagnostic test to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate
more efficient registration trials supporting a precision
medicine-based commercialisation strategy.
BerGenBio is based in Bergen,
Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo
Stock Exchange (ticker: BGBIO). For more information,
visit www.bergenbio.com
Contacts
Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513
International Media Relations
Mary-Jane Elliott, Chris
Welsh, Lucy Featherstone,
Carina Jurs
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700
Media Relations in Norway
Jan
Petter Stiff, Crux Advisers
stiff@crux.no
+47 995 13 891
Forward looking statements
This announcement may contain forward-looking statements, which
as such are not historical facts, but are based upon various
assumptions, many of which are based, in turn, upon further
assumptions. These assumptions are inherently subject to
significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and
other important factors could cause actual events to differ
materially from the expectations expressed or implied in this
announcement by such forward-looking statements.
This information is subject to the disclosure requirements
pursuant to section 5-12 of the Norwegian Securities Trading
Act.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/bergenbio-asa/r/bergenbio-virtual-r-d-day---06-november-2020,c3221309
The following files are available for download:
https://mb.cision.com/Main/15728/3221309/1322984.pdf
|
Release
|